Affiliations: [a] Xiangya School of Medicine, Third Xiangya Hospital, Central South University, Changsha, Hunan, China
| [b] Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China
| [c] Division of Biomedical Informatics & Genomics, School of Medicine, Tulane University, New Orleans, LA, USA
Correspondence:
[*]
Correspondence to: Pengfei Wu, MD, PhD, Center for Medical Genetics, School of Life Sciences, Central South University, 110 Xiangya Rd, Changsha, Hunan 410078, China. E-mail: wupengfei@sklmg.edu.cn and Yue Zhao, MPH, Center for Biomedical Informatics & Genomics, School of Medicine, Tulane University, 1440 Canal St, New Orleans, LA 70112, USA. E-mail: yzhao41@tulane.edu.
Abstract: The potential link between COVID-19 and Alzheimer’s disease (AD) has been an intriguing topic in the global pandemic. Whether the susceptibility and severity of COVID-19 affects the onset and progression of AD is of great concern. Clinical studies suggested an increased risk of AD occurrence or cognitive deficit after COVID-19. Basic research found that severe COVID-19 induced changes resembling AD. Evidence synthesis should always take into account diverse study designs, both traditional and novel. The recent study by Ding et al. aimed to investigate the association of COVID-19 with AD using a non-overlapping two-sample Mendelian randomization analysis.
